We have developed a method of specifically modifying the mammalian genome in vivo. This procedure comprises heritable tissue-specific and site-specific DNA recombination as a function of recombinase expression in transgenic mice. Transgenes encoding the bacteriophage P1 Cre recombinase and the loxP-flanked fi-galactosidase gene were used to generate transgenic mice. Genomic DNA from doubly transgenic mice exhibited tissue-specific DNA recombination as a result of Cre expression. Further characterization revealed that this process was highly efficient at distinct chromosomal integration sites. These studies also imply that Cre-mediated recombination provides a heritable marker for mitoses following the loss of Cre expression. This transgene-recombination system permits unique approaches to in vivo studies of gene function within experimentally defmed spatial and temporal boundaries.
Bacteriophage P1 encodes the 38-kDa Cre recombinase that catalyzes site-specific DNA recombination between 34-basepair (bp) repeats termed loxP (1) . Cre is a member of the integrase family of recombinases. These enzymes recognize specific nucleotide sequences and function through a transient DNA-protein covalent linkage (reviewed in refs. 2 and 3) . Cre activity appears mechanistically identical to that of yeast FLP recombinase and can function in vitro in the absence of high-energy cofactors, topoisomerase activity, and DNA replication (4, 5) . In Cre-mediated recombination, resultant DNA structures are dependent upon the orientation of loxP sites. Direct repeats of loxP dictate an excision of intervening sequences whereas inverted repeats specify inversion (4) . Cre and FLP have been shown to mediate site-specific DNA recombination in tissue-cultured eukaryotic cells, Drosophila, and transgenic plants (6) (7) (8) (9) (10) (11) (12) .
With the aim of applying Cre recombinase function to molecular studies of normal and abnormal mammalian physiology, we sought to generate a transgenic mouse system that would establish whether Cre could effectively mediate chromosomal DNA recombination. As a foundation for future applications, we devised a nondeleterious transgene strategy that would provide an assessment of the efficiency, position dependence, and heritability of Cre-mediated chromosomal DNA recombination in mammals.
MATERIALS AND METHODS
Transgene Construction and Transgenic Mouse Production. The Cre transgene expression vector was constructed by inserting the 1.5-kilobase (kb) Xho I-Xba I fragment ofpBS31 (7) , containing the Cre coding sequence, into the unique BamHI site of p1017 (ref. 13 and Fig. 1A) . A second transgene vector, in which the Escherichia coli,-galactosidase (p-gal) gene was flanked by loxP sites (Fig. 1B) , was constructed as follows. The p-gal gene, obtained as a 3.5-kb Not I fragment from pCMVB (14) , was blunt-end ligated into the BamHI site residing between two direct repeats of loxP in plasmid plox2 (derived from pBS64, 7). In plox2, two direct repeats of loxP are flanked by polylinker-derived EcoRI and HindIlI restriction enzyme sites. Isolation of the loxP-/3-galloxP fragment was followed by blunt-ended ligation into the BamHI site of p1017. Transgene vectors were purified away from plasmid sequences following Not I digestion and are represented as those Not I fragments in Fig. 1 A and B . Transgenic mice were produced following harvest of ICR X ICR zygotes (albino outbred, Harlan-Sprague-Dawley), DNA microinjection, and implantation. The presence of transgene DNA was assessed by hybridizing mouse tail DNA with either Cre orB-gal DNA probes (depicted in Fig. 1 ). In surgical procedures, 0.5 ml of 2.5% avertin was used as an anesthetic.
Southern and Northern Analysis. Thymocytes and splenocytes were harvested as single-cell suspensions by gently teasing freshly removed tissue. DNA was prepared from tissues and cells by incubation with proteinase K (100 ,g/ml; Bethesda Research Laboratories) in 100 mM Tris, pH 8.0/50 mM EDTA for 24 hr at 55°C followed by extraction with phenol/chloroform and ethanol precipitation. Purified DNA was subjected to restriction enzyme digestion and Southern blot analyses (15) . For Northern analyses, RNA was prepared from freshly homogenized tissue or single-cell suspensions in 6 M guanidinium isothiocyanate and fractionated through a CsCI cushion (16) . The RNA was denatured with formamide/formaldehyde for agarose gel electrophoresis, blotting, and hybridization (15) . DNA fragments for use as probes were nick-translated in the presence of random oligonucleotides to a specific activity of 108 cpm/,4g. Densito (13, (17) (18) (19) A Cre transgenic line (1-57) was derived from zygotes injected with the Cre expression vector depicted in Fig. 1A . Two independent transgenic lines (1-86 and 1-87) were derived from zygotes injected with the IoxP-13-gal-oxP vector (Fig. 1B) . As the ,B-gal gene is flanked by direct repeats of loxP, a Cre-mediated recombination event would be predicted to excise the 1-gal gene, generating the structure depicted in Fig. 1C . These Cre and loxP-f3-gal-loxP transgenic mouse lines bred as expected for unique single-site integration events and harbored the specific transgenes oriented as "head-to-tail" tandem arrays (data not shown), as is common for most transgene integration structures (reviewed in refs. [20] [21] [22] . Transgenic mice from the Cre and loxP-13-gal-loxP lines were then bred to generate doubly transgenic progeny.
Genomic DNA was prepared from thymocytes and tails of Cre transgenic mice, loxP-,B-gal-loxP transgenic mice, and doubly transgenic mice for Southern blot analyses. The Cre gene was visualized as the expected 2.94-kb Stu I-Msc I restriction fragment within the parental Cre transgenic mouse and a doubly transgenic offspring ( Fig. 2A , lanes 3 and 5, respectively). With a 13-gal-specific probe and the same thymocyte DNAs, the expected 2.82-kb Sac I fragment was observed in both the 1-86 and the 1-87 line ( Cre-Mediated Recombinatioi Occurs in Vivo in Transgenic Mice. Southern analysis of thymocyte DNA from double transgenic mice revealed that the 13-gal gene hybridization signal was eliminated (Fig. 2B, lane 5) . This is the expected result following Cre-mediated recombination resulting in an excision of the 13-gal gene situated between direct repeats of loxP (Fig. 1C) . Evidence for the predicted Cre-mediated recombination structure was obtained by using a loxPspecific DNA probe (Fig. 2C) . Hybridization was observed to a novel 1.60-kb Stu I-Msc I DNA fragment in the doubly transgenic thymocyte sample. Recombination was not detected in tail DNA derived from the same doubly transgenic mouse (Fig. 2C , lane 5). This new DNA structure was not present in parental thymocyte DNA derived from either the Cre or the loxP-13-galWoxP transgenic mice (Fig. 2C, lanes 2  and 3) . As would also be expected, there was a loss of the 5.14-kb DNA fragment (the double loxP-containing 13-gal transgene).
Using the polymerase chain reaction (PCR), we have cloned the recombination structure residing within the 5' Ick untranslated sequence and the second exon of hGH. Analyses with this DNA revealed the expected structural attributes, including the exact size predicted, presence of a single loxP sequence, and the expected unique polylinkerderived restriction enzyme sites flanking this novel Cregenerated loxP site (data not shown).
The 1-gal gene was incorporated as a second marker to ascertain Cre-mediated recombination by loss of 1-gal enzymatic activity, but neither the I-86 nor the 1-87 loxP-13-galIoxP transgene allele was sufficiently active to allow protein detection (data not shown). However, RNA expression was observed following quantitative PCR assays (data not shown). These studies revealed, on average, three to five molecules of transgene-derived RNA per cell. Lack of highlevel RNA expression in low-transgene-copy-number p1017-derived transgenic mice is routinely observed (unpublished observations) and does not reflect a specific inhibition mediated by loxP sites. Furthermore, studies in eukaryotic cells in vitro have shown substantial loxP-flanked gene expression at the level of both RNA and protein (6, 8, 12 (Fig. 3A and data not shown) . The predominant Cre RNA species migrated with an apparent molecular size of -3.9 kb. Analyses of these RNA samples with hGH probes, and the obvious presence of multiple Cre RNA species, provided evidence that the 3.9-kb transcripts reflected incomplete splicing of the hGH gene (data not shown). More completely spliced Cre transgene RNA was observed migrating slightly larger than 18S (-2.4 kb; Fig. 3A, lane 2) . In immunoblotting experiments using a polyclonal anti-Cre antibody (provided by Brian Sauer, DuPont) with total cellular protein derived from these tissues, we observed the predicted 38-kDa Cre recombinase specifically expressed within the thymocyte population (data not shown). This Cre expression profile is identical to that obtained from all transgenic descendents of the Cre transgenic founder animal. DNA samples from these tissues were also subjected to Southern blot analysis. In brain, kidney, liver, and tail DNAs, a-gal gene hybridization remained constant and the 1.60-kb recombination structure was not present (Fig. 3B) .
Although Cre expression was undetectable in splenocyte RNA (Fig. 3A, lane 4) , evidence of the recombination event was apparent in splenocyte DNA (Fig. 3C, lane 2) . Southern analyses of the purified splenic T-cell subpopulation (-20% of total splenocytes) revealed an enrichment for the recombination structure at the expense of the nonrecombined IoxP-,8-gal-loxP transgene allele (Fig. 3C, lane 3) . The expected loxP-hybridizing recombination product, as displayed in Fig. 2C , was also observed in this and other blotting analyses (see below). As Cre expression was not detected in either the total splenocyte or the splenic T-cell subpopulation ( Fig. 3A and data not shown), the high degree of recombination within the loxP-f3-gal-IoxP transgene array (a loss of -95% of 8-gal DNA; see below) implies that this Cremediated recombination occurred in the thymus, the natural site of T-cell ontogeny. In experiments that expanded the number of spleen-derived T cells by using the polyclonal lectin concanavalin A and interleukin 2, the recombined transgene allele frequency was retained following multiple mitoses (over at least 14 cell division cycles) in the absence of detectable Cre RNA (data not shown). These detection of the Cre transgene, the loxP-f3-gal-loxP transgene, the endogenous Ick gene, and the recombination structure (as in Fig. 3 B and C) . In comparison to the single-copy (per haploid genome) Ick gene (15) , the 1-57 Cre line was estimated to contain 110 copies of the transgene while both the 1-86 and I-87 loxP-f3-gal-oxP transgenic lines harbored -8 copies each (Fig. 4A) . Southern analyses of doubly transgenic mice from multiple matings revealed that thymocyte Cre-mediated recombination produced the expected fragment sizes in all animals surveyed, as exemplified in Fig.  4 A and B. However, variation in the degree of Cre-mediated recombination among doubly transgenic mice was observed.
To assess this variation in Cre-mediated recombination among doubly transgenic progeny, densitometric comparisons were performed using the endogenous Ick gene hybridization levels as internal controls. In these experiments, the extent of recombination was approximately 87%, 99%, and 97% in three doubly transgenic mice, as measured by loss of p-gal DNA (Fig. 4A, lanes 5-7, respectively) . In spleenderived T-cell DNA analyses, a >95% deletion of the p-gal gene was routinely observed (Fig. 3C, lane 3 , and data not shown). In identical analyses using hGH sequence as a probe, similar results were obtained (data not shown). These results represent an average of analyses undertaken on >20 doubly transgenic mice generated from seven litters.
As the IoxP-/8-gal-loxP lines harbor 8 copies of transgene per cell, removal of >88% of the total p-gal transgene (Figs. 3 and 4) . Combined with the observations that 1-gal and hGH DNA elimination can be virtually complete, and must be totally complete in some cells (perhaps those expressing the highest levels of Cre), these data imply that Cre-mediated recombination reduces the eight copies of the loxP-3-gal-loxP transgene array to a recombined allele consisting of a single copy of the Ick promoter, the residual loxP site, and the hGH gene (Fig. 1C) . This requires recombination between Ick and hGH sequences within the transgene array, as may be expected since a "head-to-tail" transgene structure would contain direct repeats of loxP flanking the 3.0-kb Ick promoter and the 2.1-kb hGH minigene. Thus at least 5.1 kb of chromosomal DNA can be excised in a single event. However, the exact distance between specific recombination events could be in integrals of 3.5 and 5.1 kb up to =70 kb, the estimated length of the transgene array.
The excised p-gal DNA is degraded, as hybridization to P-gal sequences is not observed at other chromosomal sites. Further, we were unable to detect the presence of intermediates that would reveal a sequential recombination process in transgene array reduction (data not shown). While those intermediates may nevertheless exist, they would be relatively short-lived species. These findings show that transgenic Cre-mediated recombination can be highly efficient in excising multiple DNA sequences flanked by direct repeats of loxP at a single chromosomal integration site.
Cre Can Function at Different Chromosomal Sites in Vivo. The efficiency of Cre function may also depend upon the chromosomal context of loxP sites. In this regard, a second IoxP-fp-gal-4oxP transgene line (1-87) was mated with the Cre transgenic line I-57. Breeding experiments revealed that in the 1-87 line, the IoxP-p-gal-oxP transgene is at a different chromosomal site from that of the I-86 transgenic line (data not shown). Tissue-specific Cre-mediated recombination was also detected in the progeny ofthe I-57 x I-87 cross (Fig. 4C) 24 ). However, with the recombinase approach described in this study, null alleles could be generated in a tissue-specific and developmentally regulated manner. loxP sites could be positioned, by homologous recombination, to flank the target gene/exon in a nondeleterious manner; alternatively, loxP sites could be inserted to flank a gene replacement vector for complementation of the null background. When bred into a Cre transgenic line with a predefined Cre expression profile, the exact spatial and temporal pattern of recombination would be known. This would permit reproducible studies of the immediate metabolic alterations taking place following recessive genetic lesions and also reveal tissue-specific functions for genes shown to be expressed in multiple spatial and temporal patterns. Additionally, this methodology can generate transgene ablation. A requirement for constitutive transgene expression in the evolution of developmental and pathologic phenotypes could be addressed.
The heritable nature of Cre-mediated recombination allows a significant advance in the methodology for cell fate determination in mammals. Expression of a marker gene could be engineered to be dependent upon a Cre-mediated recombination event that would excise a loxP-flanked "stop" sequence (for example a transcriptional stop and RNA splice donor site) placed between a pan-specific promoter and the marker gene. Following recombination, marker gene expression would commence. In this way daughter cells could be identified by virtue of the initial activity from the Cre transgene promoter, irrespective of subsequent Cre expression. We expect that these applications of this transgenerecombination system will greatly enhance the information gained in gene function and disease modeling research employing transgenic animals.
